Valuation: Cosmos Holdings Inc.

Market Cap 38.25M 33.65M 31.72M 28.94M 54.12M 3.67B 54.54M 381M 147M 1.87B 144M 140M 6.08B P/E 2026 *
-1.81x
P/E 2027 * 5.43x
Enterprise Value 38.25M 33.65M 31.72M 28.94M 54.12M 3.67B 54.54M 381M 147M 1.87B 144M 140M 6.08B EV / Sales 2026 *
0.47x
EV / Sales 2027 * 0.35x
Free-Float
76.24%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 60 2016-02-25
Director of Finance/CFO 43 2020-11-10
Chief Operating Officer 56 2023-01-31
Director TitleAgeSince
Director/Board Member 58 2014-01-12
Chairman 60 2016-02-25
Director/Board Member 59 2016-11-17
Change 5-day change 1-year change 3-year change Capi.($)
-5.65%-2.45% - - 38.25M
-1.27%-1.16%+14.30%+98.19% 101B
+0.61%-1.64%+44.02%+150.25% 51.55B
-0.39%+0.78%-14.33%+267.14% 20.81B
-0.25%-0.87%-11.20%-10.55% 7.93B
-1.66%-0.34%-38.67%-34.93% 6.8B
+2.75%+5.64%-1.01%+15.64% 6.52B
-0.20%-0.93%-19.00%-33.12% 5.93B
+0.46%+1.23%-2.31%+20.41% 4.95B
+1.25%+8.76%+20.44%+22.78% 4.02B
Average -0.53%+0.72%-0.86%+55.09% 23.32B
Weighted average by Cap. -0.69%-0.32%+14.39%+109.75%

Financials

2026 *2027 *
Net sales 80.8M 71.07M 67M 61.13M 114M 7.76B 115M 804M 312M 3.95B 303M 297M 12.85B 111M 97.46M 91.87M 83.82M 157M 10.64B 158M 1.1B 427M 5.41B 416M 407M 17.61B
Net income - -
Net Debt - -
Logo Cosmos Holdings Inc.
Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
Employees
-

Quarterly revenue - Rate of surprise